INS and Hyperglycemia: PTDM, defined as new-onset and persistent hyperglycaemia 3 months posttransplant in transplant recipients and present for more than 6 months [7–9], has characteristics and pathophysiological mechanisms similar to those of type 2 diabetes, e.g., insulin resistance or a decline in the production of insulin [10].